Goicoechea Miguel, Best Brookie
University California, School of Medicine, San Diego, CA 92103, USA.
Expert Opin Pharmacother. 2007 Feb;8(3):371-82. doi: 10.1517/14656566.8.3.371.
ATRIPLA (Bristol-Myers Squibb and Gilead Sciences) is a complete regimen in a single, fixed-dose combination tablet that contains: efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg. Current treatment guidelines recommend this triple combination for initial therapy because of its excellent potency, tolerability and favorable safety profile. Individually, these agents have long half-lifes that allow for once-daily dosing and may provide a pharmacologic bridge for the occasional missed dose. Although several options for once-daily regimens are available, comparative clinical trials are still in progress. This article reviews relevant efficacy and safety data of efavirenz, emtricitabine and tenofovir disoproxil fumarate, compared with other once-daily agents or certain common alternate drugs presently used as initial therapy in treatment-naive patients.
“三协唯”（百时美施贵宝公司和吉利德科学公司）是一种单片复方固定剂量的完整治疗方案，其片剂含有：600毫克依非韦伦、200毫克恩曲他滨和300毫克富马酸替诺福韦二吡呋酯。目前的治疗指南推荐这种三联组合用于初始治疗，因为它具有出色的效力、耐受性和良好的安全性。这些药物各自具有较长的半衰期，允许每日一次给药，并且对于偶尔漏服的剂量可能提供药理学上的弥补。虽然有几种每日一次治疗方案可供选择，但比较临床试验仍在进行中。本文回顾了依非韦伦、恩曲他滨和富马酸替诺福韦二吡呋酯与其他每日一次用药或目前用于初治患者初始治疗的某些常见替代药物相比的相关疗效和安全性数据。
